Will Endra Life Sciences Unit (NASDAQ:NDRAU) Run Out of Steam Soon? Short Interest is Up

July 17, 2017 - By Hazel Jackson

 Will Endra Life Sciences Unit (NASDAQ:NDRAU) Run Out of Steam Soon? Short Interest is Up

The stock of Endra Life Sciences Unit (NASDAQ:NDRAU) registered an increase of 1300% in short interest. NDRAU’s total short interest was 1,400 shares in July as published by FINRA. Its up 1300% from 100 shares, reported previously. With 900 shares average volume, it will take short sellers 2 days to cover their NDRAU’s short positions.

The stock decreased 2.69% or $0.14 on May 10, reaching $5.06. It is down 0.00% since July 17, 2016 and is . It has underperformed by 16.70% the S&P500.

ENDRA Life Sciences Inc. is engaged in commercialization of an enhanced ultrasound technology for the pre-clinical research market. The company has market cap of $. The Company’s Nexus 128 system combines light thermoacoustics and ultrasound, to address the imaging needs of researchers studying disease models in pre-clinical applications. It currently has negative earnings. The Firm is involved in developing TAEUS for incorporation into new ultrasound systems.

More notable recent ENDRA Life Sciences Inc (NASDAQ:NDRAU) news were published by: Prnewswire.com which released: “ENDRA Announces Partnership to Accelerate Development of ENDRA’s Clinical …” on May 23, 2016, also Seekingalpha.com with their article: “Endra Seeks $11 Million IPO For TAEUS Commercialization” published on December 10, 2016, Nasdaq.com published: “BUZZ-US STOCKS ON THE MOVE-Micron, Alphabet, Avis, Coach, Arconic, Grubhub …” on June 26, 2017. More interesting news about ENDRA Life Sciences Inc (NASDAQ:NDRAU) were released by: Prnewswire.com and their article: “ENDRA Life Sciences Adds Nexus 128+ to Their 3D Preclinical Photoacoustic CT …” published on September 01, 2016 as well as Reuters.com‘s news article titled: “BRIEF-Endra Life Sciences prices initial public offering” with publication date: May 09, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.